Evidence map›Paper›PMID 27823583›Full record

ArticleeLife2016

Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation.

Erin A Bassett, Nicholas Tokarew, Ema A Allemano, Chantal Mazerolle, Katy Morin, Alan J Mears, Brian McNeill, Randy Ringuette, Charles Campbell, Sheila Smiley and 14 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Wnt Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Erin A BassettRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Nicholas TokarewRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Ema A AllemanoRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Chantal MazerolleRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Katy MorinRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Alan J MearsRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Brian McNeillRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Randy RinguetteRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Charles CampbellRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Sheila SmileyRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Neno T PokrajacDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Adrian M DubucDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Vijay RamaswamyDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Paul A NorthcottDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Marc RemkeDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Philippe P MonnierGenetics and Development Division, Krembil Research Institute, University Health Network, Toronto, Canada.
David PotterDepartment of Ophthalmology, Lexicon Pharmaceuticals Inc., The Woodlands, United States.
Kim PaesDepartment of Ophthalmology, Lexicon Pharmaceuticals Inc., The Woodlands, United States.
Laura L KirkpatrickDepartment of Ophthalmology, Lexicon Pharmaceuticals Inc., The Woodlands, United States.
Kenneth J CokerDepartment of Ophthalmology, Lexicon Pharmaceuticals Inc., The Woodlands, United States.
Dennis S RiceDepartment of Ophthalmology, Lexicon Pharmaceuticals Inc., The Woodlands, United States.
Carol Perez-IratxetaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Michael D TaylorDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Valerie A WallaceRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada.ORCID 0000-0003-3721-9017
Ottawa Hospital · CALexicon Pharmaceuticals (United States) · USUniversity of Toronto · CAUniversity of Ottawa · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is a critical modulator of carcinogenesis; however, in many tumor types, the influence of the stroma during preneoplastic stages is unknown. Here we explored the relationship between pre-tumor cells and their surrounding stroma in malignant progression of the cerebellar tumor medulloblastoma (MB). We show that activation of the vascular regulatory signalling axis mediated by Norrin (an atypical Wnt)/Frizzled4 (Fzd4) inhibits MB initiation in the

Indexed as

CarcinogenesisSignal TransductionAnimalsDisease Models, AnimalEye ProteinsFrizzled ReceptorsGene Expression RegulationMedulloblastomaMiceNerve Tissue ProteinsEye ProteinsFrizzled ReceptorsFzd4 protein, mouseNdph protein, mouseNerve Tissue Proteinscancer biologydevelopmental biologyFrizzled4HedgehoghumanMedulloblastomamouseNorrinPatchedstem cellsstroma

Identifiers

PMID27823583
PMCPMC5100999
OpenAlexW2556354175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.